These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 19667501

  • 1. Venlafaxine versus SSRI therapy for major depression. Results of comparative efficacy trials.
    Bakish D.
    Postgrad Med; 1999 Nov; 106(6 Suppl):24-30. PubMed ID: 19667501
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.
    Kennedy SH, Andersen HF, Lam RW.
    J Psychiatry Neurosci; 2006 Mar; 31(2):122-31. PubMed ID: 16575428
    [Abstract] [Full Text] [Related]

  • 3. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis.
    Bauer M, Tharmanathan P, Volz HP, Moeller HJ, Freemantle N.
    Eur Arch Psychiatry Clin Neurosci; 2009 Apr; 259(3):172-85. PubMed ID: 19165525
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Venlafaxine extended-release: a review of its use in the management of major depression.
    Wellington K, Perry CM.
    CNS Drugs; 2001 Apr; 15(8):643-69. PubMed ID: 11524036
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials.
    Einarson TR, Arikian SR, Casciano J, Doyle JJ.
    Clin Ther; 1999 Feb; 21(2):296-308. PubMed ID: 10211533
    [Abstract] [Full Text] [Related]

  • 9. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study.
    McIntyre A, Gendron A, McIntyre A.
    Depress Anxiety; 2007 Feb; 24(7):487-94. PubMed ID: 17177199
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and tolerability of venlafaxine versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: a meta-analysis of published studies.
    de Silva VA, Hanwella R.
    Int Clin Psychopharmacol; 2012 Jan; 27(1):8-16. PubMed ID: 21971532
    [Abstract] [Full Text] [Related]

  • 11. Serotonin-norepinephrine reuptake inhibitor therapy in late-life depression is associated with increased marker of bone resorption.
    Shea ML, Garfield LD, Teitelbaum S, Civitelli R, Mulsant BH, Reynolds CF, Dixon D, Doré P, Lenze EJ.
    Osteoporos Int; 2013 May; 24(5):1741-9. PubMed ID: 23358607
    [Abstract] [Full Text] [Related]

  • 12. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo.
    Shelton C, Entsuah R, Padmanabhan SK, Vinall PE.
    Int Clin Psychopharmacol; 2005 Jul; 20(4):233-8. PubMed ID: 15933485
    [Abstract] [Full Text] [Related]

  • 13. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.
    Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, Factor SA, Juncos J, Serrano Ramos C, Brodsky M, Manning C, Marsh L, Shulman L, Fernandez HH, Black KJ, Panisset M, Christine CW, Jiang W, Singer C, Horn S, Pfeiffer R, Rottenberg D, Slevin J, Elmer L, Press D, Hyson HC, McDonald W, SAD-PD Study Group.
    Neurology; 2012 Apr 17; 78(16):1229-36. PubMed ID: 22496199
    [Abstract] [Full Text] [Related]

  • 14. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
    Lam RW, Lönn SL, Despiégel N.
    Int Clin Psychopharmacol; 2010 Jul 17; 25(4):199-203. PubMed ID: 20357664
    [Abstract] [Full Text] [Related]

  • 15. A case of high-dose venlafaxine-related psychosis.
    Dennison EA, Raidoo BM, Cruz R, Raidoo D.
    J Clin Psychopharmacol; 2013 Feb 17; 33(1):134-6. PubMed ID: 23288238
    [No Abstract] [Full Text] [Related]

  • 16. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo.
    Entsuah AR, Huang H, Thase ME.
    J Clin Psychiatry; 2001 Nov 17; 62(11):869-77. PubMed ID: 11775046
    [Abstract] [Full Text] [Related]

  • 17. Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies.
    Thase ME, Shelton RC, Khan A.
    J Clin Psychopharmacol; 2006 Jun 17; 26(3):250-8. PubMed ID: 16702889
    [Abstract] [Full Text] [Related]

  • 18. Reboxetine adjunct for partial or nonresponders to antidepressant treatment.
    Rubio G, San L, López-Muñoz F, Alamo C.
    J Affect Disord; 2004 Jul 17; 81(1):67-72. PubMed ID: 15183602
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of venlafaxine in the treatment of severe depression.
    Kienke AS, Rosenbaum JF.
    Depress Anxiety; 2000 Jul 17; 12 Suppl 1():50-4. PubMed ID: 11098414
    [Abstract] [Full Text] [Related]

  • 20. A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders.
    Levin FR, Mariani J, Brooks DJ, Pavlicova M, Nunes EV, Agosti V, Bisaga A, Sullivan MA, Carpenter KM.
    Addiction; 2013 Jun 17; 108(6):1084-94. PubMed ID: 23297841
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.